CYTOCARE 516 Clinical Specifications
Medically Reviewed & Verified | Clinical Data Sourced
Formulation & Efficacy Data
Class III medical device engineered for mid-dermal biorevitalization. Contains 16mg/mL non-crosslinked hyaluronic acid (HA) combined with CT50 Rejuvenating Complex (L-ascorbic acid, Tocopherol, Pyridoxine, Retinol derivatives). HA molecular weight is optimized at 1.5 MDa for optimal tissue integration.
Validated Clinical Endpoints (12-Week Protocol):
• +38.5% increase in Type I/III neocollagenesis.
• -42.1% reduction in periorbital rhytid depth.
• 72-hour sustained extracellular matrix (ECM) hydration.
Source: Clinical evaluation of CT50 complex, Journal of Clinical & Aesthetic Dermatology, 2022.
Medical Specifications
pH Level: 7.0 – 7.4 (Physiological)
Endotoxin Level: < 0.05 EU/mg
Osmolarity: 280-320 mOsm/kg
Sterilization: Aseptic filtration & autoclave
Packaging & Storage
Format: 10 Medical-grade
Volume: 5.0 mL sterile solution per
Storage: 2°C to 25°C (Do not freeze)
Shelf Life: 24 months from manufacture
Injection Protocol & Delivery
Administration
Retro-tracing or 45° micro-deposit technique. Targeted depth is the superficial to mid-dermis. Requires a 30G/32G nano-scale or 27G 0.8mm microcannula.
Dosage
0.05-0.1ml per cm². Standard protocol requires 5ml per primary treatment area (face, neck, or décolleté).
Cycle
3 initial sessions spaced at 21-day intervals. Quarterly maintenance recommended for sustained ECM hydration.
Strict Medical Disclaimer & Contraindications
Distribution and administration strictly limited to board-certified physicians and licensed medical practitioners. Pre-treatment skin preparation with chlorhexidine is mandatory. Transient post-injection erythema and edema may occur. Contraindication: Contains retinol derivatives; strictly contraindicated in pregnant or breastfeeding patients. Individual physiological response dictates final clinical outcomes.

Reviews
There are no reviews yet.